Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT01302496 is registered in ClinicalTrials.gov with Bart Neyns as lead sponsor.

NCT NCT01302496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01302496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Lead sponsor
Bart Neyns
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
January 31, 2017
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma stage iii, malignant melanoma stage iv